Abstract 882P
Background
While strong evidence indicates quitting smoking reduces the risk of developing head and neck cancer (HNC), it remains unclear whether patients who smoke could still benefit from quitting after HNC diagnosis. We investigated the impact of postdiagnosis smoking cessation on the survival of patients with HNC who smoked at diagnosis.
Methods
This prospective study included 1,298 participants who were diagnosed with HNC in the United Kingdom (Head and Neck 5000 study, recruitment: 2011-2014), and 4 countries in Latin America (Brazil, Argentina, Uruguay, and Colombia - INTERCHANGE study, recruitment: 2011-2017) who actively smoked at diagnosis. Participants have been actively followed since their diagnosis to collect regular information on their smoking behavior and disease status. Overall survival was evaluated using extended Kaplan-Meier curves and time-dependent Cox proportional hazards regression models.
Results
During the follow-up, 442 participants (34%) reported quitting smoking, and 571 deaths were recorded. Median survival time was 17 months higher when patients quit vs. continued smoking (median survival time = 6.6 vs. 5.2 years, p<0.001). At 5-years, the survival rate was significantly higher when patients quit vs. continued smoking (61.0% vs. 50.6%, p<0.001). After accounting for the quitting time and adjusting for potential confounders, quitting smoking was associated with 33% lower risk of death compared to continued smoking (HR=0.67, 95%CI=0.56-0.81). Stratified analyses revealed consistent survival benefits associated with quitting smoking among all patient subgroups, including those who reported mild-moderate vs. heavy smoking, and patients who were diagnosed with earlier vs. later-stage tumors. The benefits of quitting smoking were also evident across various HNC subtypes.
Conclusions
Quitting smoking after HNC diagnosis may significantly reduce the risk of death and improve survival among patients who smoke. These findings underscore the importance of post-diagnosis smoking cessation interventions as part of comprehensive cancer care for HNC patients.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02
880P - Paclitaxel plus cetuximab for the treatment of recurrent and/or metastatic head and neck cancer after first-line checkpoint inhibitor failure: Primary analysis from the pace ace trial
Presenter: Thorsten Fuereder
Session: Poster session 02
881P - Cetuximab with dalpicilib in patients with HPV-negative, anti-PD-1 resistant R/M HNSCC
Presenter: Ju Houyu
Session: Poster session 02
883P - Oral rehabilitation after mandibular reconstruction for head and neck malignancy: A multicenter study
Presenter: lise marie Roussel
Session: Poster session 02
884P - Real-world treatment patterns and survival outcomes associated with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN): A German claims data analysis
Presenter: Thomas Kuhnt
Session: Poster session 02
885P - Different patterns of treatment failure between p16+ and p16- patients affected by oropharyngeal carcinoma (OPC) undergoing (chemo)radiation
Presenter: Riccardo Gili
Session: Poster session 02
887P - Treatment of elderly patients with locally advanced laryngeal carcinoma with dose-intense chemotherapy followed by radio-chemotherapy: Evading surgical intervention
Presenter: Maher Salamoon
Session: Poster session 02
888P - Comparing paclitaxel plus cisplatin versus cisplatin in concurrent chemoradiotherapy for stage IV locoregionally advanced nasopharyngeal carcinoma: A phase II randomized trial
Presenter: Ling Guo
Session: Poster session 02